<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807974</url>
  </required_header>
  <id_info>
    <org_study_id>CS3150-A-J306</org_study_id>
    <nct_id>NCT02807974</nct_id>
  </id_info>
  <brief_title>Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria</brief_title>
  <official_title>A Study of CS-3150 to Evaluate Efficacy and Safety in Hypertensive Patients With Type 2 Diabetes and Albuminuria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine antihypertensive effect and safety of administration of CS-3150 in combination
      with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in sitting systolic and diastolic blood pressure</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Change from baseline in sitting systolic and diastolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of systolic and diastolic blood pressure</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Time course of systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving blood pressure control</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Proportion of patients achieving blood pressure control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change rate from baseline in urine-albumin-to-creatinine ratio</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Change rate from baseline in urine-albumin-to-creatinine ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of urine-albumin-to-creatinine ratio</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
    <description>Time course of urine-albumin-to-creatinine ratio.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CS-3150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-3150</intervention_name>
    <description>CS-3150 1.25 to 2.5, 5mg, orally</description>
    <arm_group_label>CS-3150</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 20 to 80 years at informed consent

          -  Subjects with type 2 diabetes and albuminuria (urine albumin-to-creatinine ratio ≥ 30,
             &lt; 1000 mg/g/Cr)

          -  Subjects with hypertension (Sitting SBP ≥ 140 mmHg, &lt;180 mmHg and Sitting DBP ≥ 80
             mmHg, &lt;110 mmHg

          -  Treatment with an ARB or ACE inhibitor

          -  eGFR ≥ 30 mL/min/1.73m^2

        Exclusion Criteria:

          -  Secondary hypertension or malignant hypertension

          -  Type 1 diabetes

          -  Secondary glucose intolerance

          -  Diagnosed with non-diabetic nephropathy

          -  Serum potassium level &lt; 3.5 or ≥ 4.8 mEq/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Sanuki-shi</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension with Type 2 Diabetes and Albuminuria</keyword>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Diabetic renal disease</keyword>
  <keyword>Albuminuria</keyword>
  <keyword>Mineralocorticoid receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

